NCT07121478Enrolling by invitationPhase 2
Patients With High-grade Pancreatic Neuroendocrine Tumors
Lurbinectedin as a Second-line Treatment for High-grade Pancreatic Neuroendocrine Tumors
Source: ClinicalTrials.gov · Last updated 1 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
* Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic chemotherapy is essential in cases with grade 3 pNETs or pNECs. * Cisplatin/etoposide remains the treatment of choice for high-grade pNET/pNEC. Other irinotecan-based therapies, such as FOLFIRI (cisplatin/irinotecan), FOLFOX, and temozolomide ± capecitabine, have been employed; however, a standard of care remains to be established.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 15 Jun 2025
- Start date
- 23 Sept 2025
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- National Cancer Center, Korea
- Diseases
- Neuroendocrine tumours, Pancreatic cancer
- NCT number
- NCT07121478
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 46
- From 23 Sept 2025 to the primary completion date, 1 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving treatment for other cancers (except those who completed treatment and have been disease-free for at least 2 years prior to enrollment)
Other
- Pregnant or breastfeeding women
- Deemed unsuitable for participation by the investigator due to clinical or medical reasons
Who the study is looking for
- Clinical diagnosis of Pancreatic neuroendocrine tumor or neuroendocrine carcinoma
- Documented failure of prior standard anti-cancer treatment
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³
- Platelet count ≥ 100,000 cells/mm³
- Ability to understand study content, willingness to comply with study procedures, and commitment to complete the study
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Center Coordinator of this site? Confirm its status | Goyang-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.